🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being described as a "major milestone" in the battle against superbug strains of the bacteria, according to researchers.

An International Challenge

Gonorrhoea infections are escalating globally, with data suggesting in excess of 82 million infections per year. Especially elevated rates are seen in the African continent and countries within the WHO's designated area, which includes Mongolia and China to New Zealand. In England, cases have hit a record high, while figures across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The authorization of fresh medications for gonorrhoea is an important and timely step in the context of increasing worldwide cases, the spread of superbugs and the very limited therapeutic options currently available.”

Medical experts are particularly alarmed about the surge in treatment-resistant strains. The global health body has classified it as a "priority pathogen". A tracking program showed that the effectiveness of standard treatments like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

A Pair of Novel Drugs Secure Clearance

Zoliflodacin, marketed under the name Nuzolvence, was authorized by the US FDA in recent days for combating gonorrhoea. This infection can lead to significant complications, including infertility. Researchers hope that targeted use of this new drug will help delay the emergence of superbugs.

Gepotidacin, originating from the pharmaceutical company GSK, was also approved in close succession. This treatment, which is additionally indicated for UTIs, was demonstrated in studies to be able to combat drug-resistant strains of the gonorrhoea bacteria.

An Innovative Development Model

Zoliflodacin emerged from a innovative non-profit model for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company its industry partner to develop it.

“This milestone marks a significant shift in the treatment of multidrug-resistant gonorrhoea, which until now has been outpacing our drug pipeline.”

Testing Results and Global Access

According to data released by a major medical journal, zoliflodacin cured more than 90% of uncomplicated infections. This places it at an similar efficacy with the typical regimen, which involves a dual-drug approach. The trial involved over 900 participants from several countries including the United States, Thailand, South Africa, and European nations.

Under the terms of its unique model, GARDP has the ability to register and commercialise the drug in a wide range of low-income and middle-income countries.

Doctors directly involved have voiced hope. The availability of a easy-to-administer therapy such as this is described as a "critical tool" for managing the epidemic. This is deemed vital to reduce the burden of the illness for patients and to halt the transmission of untreatable gonorrhoea around the world.